# Probiotics Rosacea Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/probiotics-rosacea-meta-analysis-evidence-review
Category: evidence-review
Summary: Probiotics Rosacea Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed 
Last reviewed: 2026-07-29
Reviewed by: Migaku Evidence Review
# Probiotics Rosacea Meta-analysis: What the Evidence Says

## Quick Answer

Probiotics Rosacea Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Neurohormonal-Immune Dysregulation in Rosacea: Emerging Perspectives from the Skin-Gut-Brain Axis | narrative review | 3 | 2026-06-16 | 10.2147/DDDT.S608151 |
| A pilot study investigating the bacterial and fungal community shifts in facial skin in rosacea | research article | 4 | 2026-06-01 | 10.1177/03000605261454625 |

## What The Sources Report

- : TLR2, Toll-like receptor 2; KLK5, kallikrein-related peptidase 5; hCAP18, human cationic antimicrobial protein 18; LL-37, cathelicidin-derived peptide; NF-κB, nuclear factor κB; NLRP3, NOD-like receptor thermal protein domain-associated protein 3; JAK/STAT, Janus kinase/signal transducer and activator of transcription; mTORC1, mammalian target of rapamycin complex 1. [Shi Lei (2026); evidence level 3]
- - Moreover, emerging evidence implicates the gut-skin axis, as dysbiosis in the gut microbiota may contribute to the pathogenesis of rosacea through immune modulation, opening avenues for probiotic interventions but failing to address direct fungal involvement. [Tang Xiaobin (2026); evidence level 4]
- To address this, our study provides the first comprehensive dual-kingdom analysis of rosacea-associated microbiome alterations by simultaneously examining bacterial (via 16S rRNA sequencing) and fungal (via ITS sequencing) communities in facial samples from patients with rosacea and healthy controls. [Tang Xiaobin (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For probiotics rosacea meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Shi Lei (2026). Neurohormonal-Immune Dysregulation in Rosacea: Emerging Perspectives from the Skin-Gut-Brain Axis. DOI: 10.2147/DDDT.S608151. PMCID: PMC13282955. PMID: 42325915. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13282955/
- Tang Xiaobin (2026). A pilot study investigating the bacterial and fungal community shifts in facial skin in rosacea. DOI: 10.1177/03000605261454625. PMCID: PMC13254424. PMID: 42270571. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13254424/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.